MiMedx Group, Inc. (MDXG)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Buy stop 4.81: breakout above the settled 4.80 double-top resistance (09-15/09-18 regular-session highs) on a 3.9M-share accumulation day. Protective stop 4.58 below the 09-18 swing low 4.614 and the 4.61-4.66 consolidation floor (1.28x ATR risk). Targets 5.17 (2.0x ATR) and 5.44 (3.5x ATR); R/R 1.57 vs target 1. All gates passed: fundamentalScore 3 and qualitativeScore 3, 20-day dollar volume $5.11M, recent 3-session $4.08M, max overnight gap 1.16%, ATR 3.77% of price, no earnings/dividend events inside the 15-day window (horizon 2026-10-09; next earnings 2026-11-04).
Company overview
MiMedx Group, Inc. develops and supplies allografts derived from placental tissue for various medical applications. The company uses its proprietary PURION process to treat human placental tissues, ensuring product safety and efficacy. Its products, such as EpiFix and AmnioFix, are used in wound care, surgical recovery, and burn treatment.
Fundamental
fairStrong historical performance is overshadowed by reimbursement changes and acquisition risks, leading to a mixed outlook.
Mixed: MDXG has strong historical margins, free-cash-flow generation and a net-cash balance sheet, making the stock look cheap on FY2025 multiples. But 2026 reimbursement changes have already driven a major wound-care revenue drop and quarterly losses, and the announced debt-funded acquisition adds execution and leverage risk. FundamentalScore: 3/5.
Sentiment
fairSentiment is forming with no recent negative coverage, but the setup remains mixed due to pending acquisition and reimbursement concerns.
Dominant near-term driver is the pending, announced $350M Sanara MedTech acquisition (ongoing_process; reception-positive — the July announcement cluster scored +0.45 to +0.60 — still unresolved and partially priced). The sentiment delta is indeterminate at the aggregate level because the 14-day scoring window carried no substantive scorable coverage (one neutral conference notice; two law-firm solicitations filtered), with an item-level fallback read of neutral against a determinate-bullish baseline (+0.375); the Red-Flag Screen is clean and no cap applies.
Technical
goodThe stock is in a recovery uptrend, with a breakout above 4.80 resistance supported by strong volume.
Trend: close 4.77 sits above SMA20 4.55, SMA50 4.37, SMA200 4.62, EMA9 4.67 and the 09-18 daily VWAP 4.71 - full bullish alignment with the short-term average stack (EMA9 > SMA20 > EMA21) turning up. Momentum: RSI14 64.7 is bullish but not overbought, MACD line 0.11 is above signal 0.10 and above zero with histogram +0.01, and ADX14 22.4 is rising (from 19.2 on 09-08) - trend strength improving though still below 25. The one weak signal is Williams %R at -6.7, near the overbought extreme. Volume: 09-18 printed 3,902,610 shares (~3.4x the ~1.1M-share recent daily average), the heaviest session since the 07-30 earnings surge, and it was an up day - accumulation confirming the grind higher. Structure: 4.80 has been tagged twice as the regular-session high (09-15 and 09-18), forming a settled double top; the last two sessions' consolidation floor is 4.61-4.66. A buy stop at 4.81 clears that double top with no 2026 overhead above it. Protective stop 4.58 sits below the 09-18 swing low 4.614 minus a 0.04 buffer, and below the two-session floor, clear of normal retest noise (risk 0.23 = 1.28x ATR, above the 0.5x floor). Targets 5.17 (2.0x ATR) and 5.44 (3.5x ATR) lie in open space; computed R/R vs target 1 is 1.57.
You’re looking at 2026-09-19 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.